103788-64-3

Usage

Uses

Used in Fragrance Industry:
METHYL 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETATE is used as a fragrance ingredient in perfumes and other scented products for its pleasant odor, enhancing the sensory experience of consumers.
Used in Pharmaceutical Manufacturing:
METHYL 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETATE is utilized in the manufacturing of pharmaceuticals, contributing to the development of new drugs and medicinal compounds due to its unique chemical structure.
Used in Organic Synthesis:
METHYL 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETATE has potential applications in the field of organic synthesis, where it can serve as a building block or intermediate in the synthesis of more complex organic compounds.
Used in Medicinal Chemistry:
It also finds use in medicinal chemistry, where its properties may be leveraged to create new therapeutic agents or improve existing ones, potentially leading to advancements in healthcare.

InChI:InChI=1/C13H13NO3/c1-9-11(8-12(15)16-2)14-13(17-9)10-6-4-3-5-7-10/h3-7H,8H2,1-2H3

Upstream product

• 55-21-0 benzamide 
• 105983-77-5 methyl 4-bromo-3-oxopentanoate 
• 30414-53-0 methyl propanoyl acetate 
• 67-56-1 methanol 
• 524959-64-6 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetonitrile 
• 98-88-4 benzoyl chloride 
• 39741-26-9 N-benzoyl-L-aspartic acid β-methyl ester 
• 54819-26-0 methyl 3-(benzoylamino)-4-oxovalerate 
• 100373-13-5 methyl 3-benzamido-4-oxovalerate 

Downstream Products

• 103788-65-4 (5-methyl-2-phenyloxazol-4-yl)ethanol 
• 107367-98-6 2-(5-Methyl-2-phenyl-4-oxazolyl)-acetic acid 
• 174258-60-7 1-{3-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethanone 
• 227029-27-8 2-(2-phenyl-5-methyloxazole-4-yl)ethyl methanesulfonate 
• 199794-42-8 3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propionic acid 
• 159018-02-7 methyl 3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propionate 
• 103788-59-6 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzaldehyde 
• 244152-94-1 3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzaldehyde 
• 1027436-20-9 1-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethanone 
• 1026127-44-5 3-fluoro-4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzaldehyde 
• 103788-87-0 4-<2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy>aniline 
• 103789-44-2 4-<2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy>benzonitrile 
• 103788-72-3 4-<2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy>nitrobenzene 
• 103814-35-3 methyl 2-bromo-3-{4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl}propionate 

Relevant academic research and scientific papers

Synthesis and antimicrobial evaluation of 3-methanone-6-substituted- benzofuran derivatives

Seventeen benzofuran derivatives were synthesized and screened for their antibacterial activities against Escherichia coli, Staphylococcus aureus, Methicillin-resistant S. aureus, Bacillus subtilis, and Pseudomonas aeruginosa. Seven of them have showed excellent antibacterial activities compared to the positive controls (Cefotaxime and Sodium Penicillin). The substitutions at C-6 and C-3 positions of these derivatives were found to greatly impact on the antibacterial activity and strains specificity, respectively. Specifically, compounds bearing a hydroxyl group at C-6 (5a, 5b, 5c and 12) offered excellent antibacterial activities against all five above-mentioned strains (MIC 80 = 0.78-12.5 ug/mL), and those with imine (15) and (3, 4, 5-trimethoxyphenyl) methanone (7e), respectively, at C-3 position showed selective activity against S. aureus among five tested strains with great MIC80 values (3.12-12.5 ug/mL).

Design, synthesis and antimicrobial activity of chiral 2-(substituted- hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives

Chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives were synthesized and their antibacterial activities were evaluated against fungus, Gram-negative and Gram-positive bacteria. In general, these compounds showed in vitro acti

(S)-3-(4-(2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-(piperazin-1-yl)propanoic acid compounds: Synthesis and biological evaluation of dual PPARα/γ agonists

A series of novel, potent PPARα/γ dual agonists were synthesized and appraised. The most potent analogue, compound 2b demonstrated EC50 value of 0.012 ± 0.002 and 0.032 ± 0.01 μM, respectively, for hPPARα and hPPARγ in transactivation assay. Additionally, compound 2b demonstrated good glucose and lipid lowering effect in genetic diabetic (db/db) mice.

Process development and scale-up of AG035029

A practical process for the synthesis of PPARγ agonist AG035029 was developed which involved six steps along the longest linear path. The process development utilized automated technology and computational chemistry extensively to accelerate the speed of

TYROSINE DERIVATIVES SUBSTITUTED BY N-PHENYLACRYLOYL AS AGONISTS OF HPPAR ALPHA AND HPPAR GAMA

The present invention relates to a compound of formula I, racemates, optically active isomers, or pharmaceutically acceptable salts or solvates thereof, and a pharmaceutical composition comprising the compound, the various radicals in the formula I are the same as defined in the claims. The present invention also relates to a process for preparing the compound of formula I and use of said compound in the preparation of a medicament for the treatment of hyperglycemia, dyslipidemia, type II diabetes mellitus including associated diabetic dyslipidemia

Substitued A-Piperazingly Phenylpropionic Acid Derivatives As Hppar Alpha And/Or Hppar Gamma Agonists

The present invention relates to a compound of formula I, racemates, optically active isomers, or pharmaceutically acceptable salts or solvates thereof, and a pharmaceutical composition comprising the compound, the various radicals in the formula I are the same as defined in the claims. The present invention also relates to a process for preparing the compound of formula I and use of said compound in the preparation of a medicament for the treatment of hyperglycemia, dyslipidemia, type II diabetes mellitus including associated diabetic dyslipidemia

PROCESS FOR PREPARING OXAZOLE CARBOXYLIC ESTERS

A process for preparing oxazole carboxylic esters of the formula (I) in which Ar is aryl or heteroaryl, Rl is H or alkyl and R2 is alkyl or aryl, which comprises converting an oxazole nitrile of the formula (II) in which Ar and Rl are as defined above, in the presence of a mineral acid and of ' an alcohol of the formula R20H, and subsequent hydrolysis with water, into the desired oxazole carboxylic esters of the formula (I) .

NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

The present invention relates to novel compounds accelerating the activity of Peroxisome proliferator-activated receptor gamma (PPARγ) and alpha (PPARα), processes of preparing the same, and pharmaceutical compositions containing the same as an active agent.

Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis

The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.

1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof

The invention relates to combinatorial libraries containing two or more novel piperidine-3-carboxamide derivative compounds, methods of preparing the piperidine-3-carboxamide derivative compounds and piperidine-3-carboxamide derivative compounds bound to a resin